Clinilabs Expands Phase I Facility


Company News Release

Clinilabs, Inc., a specialty contract research organization (CRO), has completed expansion of its Phase I unit.

New York, NY (August 6, 2008) – Clinilabs, Inc., a specialty contract research organization (CRO), has completed expansion of its Phase I unit.  This expansion brings the Company’s Phase I facility to 68-beds, which includes two new large observation rooms that can accommodate up to four beds each, or up to 12 PK seats.  

The Company conducts Phase I studies in any therapeutic area, including pharmacokinetic (PK), pharmacodynamic (PD), bioavailability (BA), bioequivalence (BE), drug interaction, and food interaction studies.  Additionally, Clinilabs offers specialty services for complex PD studies, such as those that involve the collection of mood, cognition, psychomotor functioning, EEG, quantitative EEG, evoked potential (EP), and imaging data.
“Phase I studies are becoming increasingly complex and sponsors depend on data from these studies to make crucial decisions about their development programs,” stated Dr. Gary Zammit, President and CEO of Clinilabs. “Clinilabs’ state-of-the-art facility is an ideal location for pharmaceutical and biotechnology companies looking for outstanding service for their Phase I studies,” he added.
Conveniently located in New York City, Clinilabs can recruit patients from a large and diverse population, including healthy adult, healthy elderly, Japanese, Chinese, and key patient populations.  In addition, Clinilabs’ metropolitan location provides sponsors, as well as patients, with easy access to transportation hubs and major subway and bus lines.        

Clinilabs Phase I facility is staffed with highly qualified physicians, nurses, and research associates, providing service 24 hours a day, 7 days a week.    
About Clinilabs, Inc.

Clinilabs is a specialty contract research organization (CRO) that provides a full portfolio of services to pharmaceutical, biotechnology, and medical device companies involved in the development of central nervous system (CNS) and cardiovascular (CV) therapeutics.  The Company also provides early phase services in a wider range of therapeutic areas at its Phase I facility. Established in 2001, Clinilabs has provided services to more than one third of the world’s top 20 pharmaceutical companies, and has been involved in 7 successful New Drug Applications (NDAs) in central nervous system (CNS) and cardiovascular (CV) indications.  For more information, please visit <

> .

Related Videos
Greg Ball, Founder, ASAP Process Consulting image credit screen shot from video
Janice Chang, CEO, TransCelerate BioPharma @ video screenshot.
Applied Clinical Trials and LabConnect
Related Content
© 2024 MJH Life Sciences

All rights reserved.